🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Late fall and still beautiful.

Coffee science and collaboration. A perfect day even if the weather is bad here in Manhattan at Perlmutter Cancer Center at NYU Langone Health annual retreat.

Evolution of Rapid Clonal Dynamics and Non-Cross-Resistance in Response to Alternating Targeted Therapy and Chemoth… pubmed.ncbi.nlm.nih.gov/39626159/ Translational publication from our group. Important to have the scientists and clinicians talking in the same room.

Au contraire, my friend. You are standing right where you are meant to be.

I always come back feeling refreshed. Thank you Paolo A. Ascierto for your vision in forming the Bridge.

I always enjoy publishing with Matteo Carlino and crew! Outcomes following long-term disease control with immune checkpoint in... sciencedirect.com/science/articl…

Saved the wine generously gifted by Paolo A. Ascierto to go with our seven fishes for an Italian Christmas Eve. Merry Everything to Everyone.

Another important analysis led by Matteo Carlino featuring contributions from our team Perlmutter Cancer Center at NYU Langone Health. Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma pubmed.ncbi.nlm.nih.gov/39667250/

Thanks ⁦MayoClinicHealthSystem⁩ for inviting me to talk about one of my favorite topics, neoadjuvant therapy for the treatment of melanoma.

I enjoyed working with this team to publish our experience in skin toxicities from cancer immunotherapy. NYU Grossman School of Medicine Characterizing Chronic Cutaneous Immune-Related Adverse Events Following Immune Checkpoint Inhibitors pubmed.ncbi.nlm.nih.gov/40072456/

Thank you Seamus O’Reilly MD PhD. I miss him terribly but I am grateful for the lessons he taught me in life and leadership.

Our published experience below from Perlmutter Cancer Center at NYU Langone Health in melanoma brain metastases. Outcomes of concurrent versus non-concurrent immune checkpoint inhibition with stereotactic radiosurgery for melano… pubmed.ncbi.nlm.nih.gov/40183901/

Very exciting work, Phase 3 open now at Perlmutter Cancer Center at NYU Langone Health - first site in New York/NJ!

💯

Congrats to Teru and Amrutesh S. Puranik on fine work! Mentoring this team brings me much joy.

He departed from his new wife to serve in Africa, France and Germany. His service earned two Purple Heart awards. I am in awe when I think of the sacrifice. I was nine when he died, but I remember his stern, yet loving nature. I would give anything to see him. Thank you,Grandpa.

Amazing representation of NYU Langone Health Perlmutter Cancer Center at NYU Langone Health at #ASCO25 Joshua Sabari, MD Janice Mehnert, MD Peter Yu Kenneth Csehak Jr., MD Elaine Shum

I presented data from our trial of ipi, nivo, rela and IL-6 receptor inhibitor sarilumab in metastatic melanoma. Improved response rate, and toxicity way down!Now confirming in a randomized cohort +/- sari.A patient-centered approach addressing both efficacy and tolerability.

Excited to have been a part of this work, led by Dr. Kirchhoff and Dr. Monson.

There is no greater pleasure than watching one of your mentees achieve this stellar career milestone!